IMVT — Immunovant Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapNeutral

Annual balance sheet for Immunovant, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash
Cash and Short Term Investments	101	400	494	377	635
Net Total Accounts Receivable
Net Total Receivables	3.04	0.548	12.9	0.885	5.5
Prepaid Expenses
Total Current Assets	109	409	513	404	666
Net Property, Plant And Equipment	0.065	3.48	2.63	1.5	0.595
Other Long Term Assets
Total Assets	109	412	516	406	666
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	15.3	18.8	44.5	43.3	48.6
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	15.3	21	45.7	43.3	48.6
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	94.1	391	470	362	618
Total Liabilities & Shareholders' Equity	109	412	516	406	666
Total Common Shares Outstanding